Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Addex Therapeutics

< Previous 1 2 Next >
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Convenes Extraordinary General Meeting
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
From Addex Therapeutics
Via GlobeNewswire
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
From Addex Therapeutics
Via GlobeNewswire
Addex Regains Nasdaq Listing Compliance
From Addex Therapeutics
Via GlobeNewswire
Addex Announces Participation in the Bio-Europe 2023 Conference
From Addex Therapeutics
Via GlobeNewswire
Addex Completes ADS Ratio Change
From Addex Therapeutics
Via GlobeNewswire
Addex Announces Plan to Implement ADS Ratio Change
From Addex Therapeutics
Via GlobeNewswire
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
From Addex Therapeutics
Via GlobeNewswire
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
From Addex Therapeutics
Via GlobeNewswire
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
From Addex Therapeutics
Via GlobeNewswire
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
From Addex Therapeutics
Via GlobeNewswire
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
From Addex Therapeutics
Via GlobeNewswire
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
From Addex Therapeutics
Via GlobeNewswire
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
From Addex Therapeutics
Via GlobeNewswire
Addex Increases Issued Share Capital to Create Treasury Shares
From Addex Therapeutics
Via GlobeNewswire
Addex Shareholders Approve All Resolutions at Annual General Meeting
From Addex Therapeutics
Via GlobeNewswire
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From Addex Therapeutics
Via GlobeNewswire
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
From Addex Therapeutics
Via GlobeNewswire
Addex Convenes Annual General Meeting 2023
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
From Addex Therapeutics
Via GlobeNewswire
Addex Completes $5.0 Million Equity Financing
From Addex Therapeutics
Via GlobeNewswire
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
From Addex Therapeutics
Via GlobeNewswire
Addex Raises $5.0 Million in Equity Financing
From Addex Therapeutics
Via GlobeNewswire
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
From Addex Therapeutics
Via GlobeNewswire
Addex Announces Upcoming Conferences it will participate for H1 2023
From Addex Therapeutics
Via GlobeNewswire
Addex Regains Nasdaq Listing Compliance
From Addex Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.